logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for medical industry professionals · Wednesday, February 26, 2025 · 789,367,901 Articles · 3+ Million Readers
Got News to Share? Send 2 FREE Releases ↓
News Search | All News Topics > Lung Cancer News Topics: By Country | By State ; Press Releases by Industry Channel > All Lung Cancer Press Releases

Enamine, Chemspace, and PharmAI Discovery Join Forces to Advance AI-Driven Drug Discovery for Novel Theranostics

DRESDEN, GERMANY, February 26, 2025 /EINPresswire.com/ -- ๐„๐ง๐š๐ฆ๐ข๐ง๐ž, ๐‚๐ก๐ž๐ฆ๐ฌ๐ฉ๐š๐œ๐ž, and ๐๐ก๐š๐ซ๐ฆ๐€๐ˆ ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐†๐ฆ๐›๐‡ (๐๐€๐ˆ๐ƒ) start a transformative collaboration to accelerate the advancement of theranostics through AI-driven drug discovery with emphasis on cancer diagnosis and therapy. This collaboration brings together the success of Enamineโ€™s discovery biology and chemistry competencies, Chemspaceโ€™s expertise in ultra-large chemical space exploration for drug discovery, and PAIDโ€™s AI-powered molecular discovery platform to identify and develop promising drug candidates faster and with greater precision, both for conventional and molecular radiotherapy and radio diagnostics. Specific modulator molecules labeled with a radioisotope can target various cancers highly selective and locate such cancer cells for diagnosis or deliver precisely radiation for their destruction. The recent successes in radioligand therapy (RLT) in the clinic, regulatory breakthrough therapy designations, product approvals, and broad technology advancements catalyzed considerable growth in this field, evident by new company formations and market expansion. This partnership allows for the critical acceleration of the Design-Make-Test-Analyze cycle of potential compounds for RLT, saving time towards new treatments for cancer patients with still unmet medical needs.

โ€œ๐‘Š๐‘’ ๐‘Ž๐‘Ÿ๐‘’ ๐‘’๐‘ฅ๐‘๐‘–๐‘ก๐‘’๐‘‘ ๐‘ก๐‘œ ๐‘๐‘’ ๐‘Ž ๐‘๐‘Ž๐‘Ÿ๐‘ก ๐‘œ๐‘“ ๐‘กโ„Ž๐‘–๐‘  ๐‘๐‘œ๐‘™๐‘™๐‘Ž๐‘๐‘œ๐‘Ÿ๐‘Ž๐‘ก๐‘–๐‘œ๐‘› ๐‘กโ„Ž๐‘Ž๐‘ก ๐‘”๐‘–๐‘ฃ๐‘’๐‘  ๐‘ข๐‘  ๐‘กโ„Ž๐‘’ ๐‘œ๐‘๐‘๐‘œ๐‘Ÿ๐‘ก๐‘ข๐‘›๐‘–๐‘ก๐‘ฆ ๐‘ก๐‘œ ๐‘ข๐‘ ๐‘’ ๐‘œ๐‘ข๐‘Ÿ ๐‘ข๐‘›๐‘–๐‘ž๐‘ข๐‘’ ๐‘Ž๐‘๐‘๐‘Ÿ๐‘œ๐‘Ž๐‘โ„Ž๐‘’๐‘  ๐‘ก๐‘œ ๐‘’๐‘ฅ๐‘๐‘™๐‘œ๐‘Ÿ๐‘Ž๐‘ก๐‘–๐‘œ๐‘› ๐‘œ๐‘“ ๐‘ข๐‘™๐‘ก๐‘Ÿ๐‘Ž-๐‘™๐‘Ž๐‘Ÿ๐‘”๐‘’ ๐‘โ„Ž๐‘’๐‘š๐‘–๐‘๐‘Ž๐‘™ ๐‘ ๐‘๐‘Ž๐‘๐‘’๐‘  ๐‘™๐‘–๐‘˜๐‘’ ๐ธ๐‘›๐‘Ž๐‘š๐‘–๐‘›๐‘’ ๐‘…๐ธ๐ด๐ฟโ„ข ๐‘Ž๐‘›๐‘‘ ๐น๐‘Ÿ๐‘’๐‘’๐‘‘๐‘œ๐‘š ๐‘†๐‘๐‘Ž๐‘๐‘’โ„ข ๐‘Ž๐‘  ๐‘Ž ๐‘ ๐‘œ๐‘ข๐‘Ÿ๐‘๐‘’ ๐‘œ๐‘“ ๐‘ž๐‘ข๐‘Ž๐‘™๐‘–๐‘“๐‘–๐‘’๐‘‘ ๐‘ ๐‘ก๐‘Ž๐‘Ÿ๐‘ก๐‘–๐‘›๐‘” ๐‘๐‘œ๐‘–๐‘›๐‘ก๐‘  ๐‘“๐‘œ๐‘Ÿ ๐‘‘๐‘–๐‘ ๐‘๐‘œ๐‘ฃ๐‘’๐‘Ÿ๐‘ฆ ๐‘๐‘Ÿ๐‘œ๐‘—๐‘’๐‘๐‘ก๐‘  ๐‘Ž๐‘  ๐‘ค๐‘’๐‘™๐‘™ ๐‘Ž๐‘  ๐‘“๐‘œ๐‘™๐‘™๐‘œ๐‘ค-๐‘ข๐‘ ๐‘ ๐‘ก๐‘ข๐‘‘๐‘–๐‘’๐‘ , ๐‘’๐‘ ๐‘๐‘’๐‘๐‘–๐‘Ž๐‘™๐‘™๐‘ฆ ๐‘–๐‘› โ„Ž๐‘–๐‘ก-๐‘ก๐‘œ-๐‘™๐‘’๐‘Ž๐‘‘ ๐‘Ž๐‘›๐‘‘ ๐‘™๐‘’๐‘Ž๐‘‘-๐‘œ๐‘๐‘ก๐‘–๐‘š๐‘–๐‘ง๐‘Ž๐‘ก๐‘–๐‘œ๐‘›,โ€ ๐‘ ๐‘Ž๐‘–๐‘‘ ๐‘‚๐‘™๐‘”๐‘Ž ๐‘‡๐‘Ž๐‘Ÿ๐‘˜โ„Ž๐‘Ž๐‘›๐‘œ๐‘ฃ๐‘Ž, ๐ถ๐ธ๐‘‚ ๐‘Ž๐‘ก ๐ถโ„Ž๐‘’๐‘š๐‘ ๐‘๐‘Ž๐‘๐‘’. โ€œ๐‘Š๐‘’ ๐‘Ž๐‘Ÿ๐‘’ ๐‘’๐‘ฅ๐‘๐‘’๐‘๐‘ก๐‘–๐‘›๐‘” ๐‘ก๐‘œ ๐‘‘๐‘’๐‘ ๐‘–๐‘”๐‘›, ๐‘–๐‘‘๐‘’๐‘›๐‘ก๐‘–๐‘“๐‘ฆ, ๐‘Ž๐‘›๐‘‘ ๐‘‘๐‘’๐‘ฃ๐‘’๐‘™๐‘œ๐‘ ๐‘๐‘Ÿ๐‘œ๐‘š๐‘–๐‘ ๐‘–๐‘›๐‘” ๐‘‘๐‘Ÿ๐‘ข๐‘” ๐‘๐‘Ž๐‘›๐‘‘๐‘–๐‘‘๐‘Ž๐‘ก๐‘’๐‘  ๐‘›๐‘œ๐‘ก ๐‘—๐‘ข๐‘ ๐‘ก ๐‘“๐‘Ž๐‘ ๐‘ก๐‘’๐‘Ÿ ๐‘๐‘ข๐‘ก ๐‘Ž๐‘™๐‘ ๐‘œ ๐‘ค๐‘–๐‘กโ„Ž ๐‘”๐‘Ÿ๐‘’๐‘Ž๐‘ก๐‘’๐‘Ÿ ๐‘๐‘Ÿ๐‘’๐‘๐‘–๐‘ ๐‘–๐‘œ๐‘› ๐‘๐‘’๐‘๐‘Ž๐‘ข๐‘ ๐‘’ ๐‘œ๐‘“ ๐‘‘๐‘œ๐‘ฃ๐‘’๐‘ก๐‘Ž๐‘–๐‘™๐‘–๐‘›๐‘” ๐‘œ๐‘ข๐‘Ÿ ๐‘๐‘œ๐‘š๐‘๐‘’๐‘ก๐‘’๐‘›๐‘๐‘–๐‘’๐‘ .โ€

โ€๐ท๐‘Ÿ๐‘’๐‘ ๐‘‘๐‘’๐‘›, ๐‘†๐‘Ž๐‘ฅ๐‘œ๐‘›๐‘ฆ ๐‘–๐‘› ๐บ๐‘’๐‘Ÿ๐‘š๐‘Ž๐‘›๐‘ฆ ๐‘–๐‘  ๐‘œ๐‘›๐‘’ ๐‘œ๐‘“ ๐‘กโ„Ž๐‘’ ๐‘ค๐‘œ๐‘Ÿ๐‘™๐‘‘ ๐‘™๐‘’๐‘Ž๐‘‘๐‘–๐‘›๐‘” ๐‘๐‘’๐‘›๐‘ก๐‘’๐‘Ÿ๐‘  ๐‘–๐‘› ๐‘Ÿ๐‘Ž๐‘‘๐‘–๐‘œ๐‘โ„Ž๐‘Ž๐‘Ÿ๐‘š๐‘Ž๐‘๐‘ฆ ๐‘’๐‘ฃ๐‘–๐‘‘๐‘’๐‘›๐‘ก ๐‘๐‘ฆ ๐‘กโ„Ž๐‘’ ๐‘Ž๐‘๐‘๐‘Ÿ๐‘œ๐‘ฃ๐‘Ž๐‘™ ๐‘œ๐‘“ ๐‘ก๐‘Ÿ๐‘Ž๐‘›๐‘ ๐‘“๐‘œ๐‘Ÿ๐‘š๐‘Ž๐‘ก๐‘–๐‘ฃ๐‘’ ๐‘Ÿ๐‘Ž๐‘‘๐‘–๐‘œ๐‘กโ„Ž๐‘’๐‘Ÿ๐‘Ž๐‘›๐‘œ๐‘ ๐‘ก๐‘–๐‘๐‘ ,โ€ ๐‘ ๐‘Ž๐‘–๐‘‘ ๐‘Œ๐‘ข๐‘Ÿ๐‘–๐‘– ๐‘€๐‘œ๐‘Ÿ๐‘œ๐‘ง, ๐‘‰๐‘–๐‘๐‘’ ๐‘ƒ๐‘Ÿ๐‘’๐‘ ๐‘–๐‘‘๐‘’๐‘›๐‘ก ๐‘œ๐‘“ ๐‘†๐‘Ž๐‘™๐‘’๐‘  ๐‘Ž๐‘›๐‘‘ ๐‘€๐‘Ž๐‘Ÿ๐‘˜๐‘’๐‘ก๐‘–๐‘›๐‘” ๐‘œ๐‘“ ๐ธ๐‘›๐‘Ž๐‘š๐‘–๐‘›๐‘’. โ€œ๐‘‡โ„Ž๐‘’ ๐‘๐‘œ๐‘š๐‘๐‘–๐‘›๐‘Ž๐‘ก๐‘–๐‘œ๐‘› ๐‘œ๐‘“ ๐‘ ๐‘ข๐‘โ„Ž ๐‘’๐‘ฅ๐‘๐‘’๐‘Ÿ๐‘ก๐‘–๐‘ ๐‘’ ๐‘๐‘ฆ ๐‘ƒโ„Ž๐‘Ž๐‘Ÿ๐‘š๐ด๐ผ ๐ท๐‘–๐‘ ๐‘๐‘œ๐‘ฃ๐‘’๐‘Ÿ๐‘ฆ, ๐‘๐‘Ž๐‘ก๐‘Ž๐‘™๐‘ฆ๐‘ง๐‘’๐‘‘ ๐‘๐‘ฆ ๐ด๐ผ/๐‘€๐ฟ, ๐‘ค๐‘–๐‘กโ„Ž ๐ถโ„Ž๐‘’๐‘š๐‘ ๐‘๐‘Ž๐‘๐‘’โ€™๐‘  ๐‘Ž๐‘๐‘–๐‘™๐‘–๐‘ก๐‘–๐‘’๐‘  ๐‘ก๐‘œ ๐‘’๐‘“๐‘“๐‘’๐‘๐‘ก๐‘–๐‘ฃ๐‘’๐‘™๐‘ฆ ๐‘’๐‘ฅ๐‘๐‘™๐‘œ๐‘Ÿ๐‘’ ๐‘กโ„Ž๐‘’ ๐‘–๐‘š๐‘š๐‘’๐‘›๐‘ ๐‘’๐‘™๐‘ฆ ๐‘’๐‘ฅ๐‘๐‘™๐‘œ๐‘‘๐‘’๐‘‘ ๐‘โ„Ž๐‘’๐‘š๐‘–๐‘๐‘Ž๐‘™ ๐‘ ๐‘๐‘Ž๐‘๐‘’, ๐‘๐‘™๐‘ข๐‘  ๐ธ๐‘›๐‘Ž๐‘š๐‘–๐‘›๐‘’โ€™๐‘  ๐‘ข๐‘›๐‘“๐‘Ž๐‘™๐‘ก๐‘’๐‘Ÿ๐‘–๐‘›๐‘” ๐‘๐‘œ๐‘š๐‘š๐‘–๐‘ก๐‘š๐‘’๐‘›๐‘ก ๐‘ก๐‘œ ๐‘ ๐‘ฆ๐‘›๐‘กโ„Ž๐‘’๐‘ ๐‘–๐‘ง๐‘’ ๐‘Ž๐‘›๐‘‘ ๐‘’๐‘ฃ๐‘Ž๐‘™๐‘ข๐‘Ž๐‘ก๐‘’ ๐‘ค๐‘–๐‘กโ„Ž โ„Ž๐‘–๐‘”โ„Ž ๐‘๐‘Ÿ๐‘œ๐‘๐‘Ž๐‘๐‘–๐‘™๐‘–๐‘ก๐‘ฆ ๐‘Ÿ๐‘Ž๐‘๐‘–๐‘‘๐‘™๐‘ฆ ๐‘›๐‘œ๐‘ฃ๐‘’๐‘™ ๐‘š๐‘Ž๐‘˜๐‘’-๐‘œ๐‘›-๐‘‘๐‘’๐‘š๐‘Ž๐‘›๐‘‘ ๐‘๐‘œ๐‘š๐‘๐‘œ๐‘ข๐‘›๐‘‘๐‘ , ๐‘‘๐‘Ÿ๐‘–๐‘ฃ๐‘’๐‘› ๐‘๐‘ฆ ๐‘š๐‘’๐‘‘๐‘–๐‘๐‘–๐‘›๐‘Ž๐‘™ ๐‘โ„Ž๐‘’๐‘š๐‘–๐‘ ๐‘ก๐‘Ÿ๐‘ฆ ๐‘Ž๐‘›๐‘‘ ๐‘‘๐‘–๐‘ ๐‘’๐‘Ž๐‘ ๐‘’ ๐‘๐‘–๐‘œ๐‘™๐‘œ๐‘”๐‘ฆ, ๐‘๐‘œ๐‘›๐‘ ๐‘ก๐‘–๐‘ก๐‘ข๐‘ก๐‘’๐‘  ๐‘Ž ๐‘๐‘œ๐‘ค๐‘’๐‘Ÿ๐‘“๐‘ข๐‘™ ๐‘…&๐ท ๐‘Ž๐‘™๐‘™๐‘–๐‘Ž๐‘›๐‘๐‘’ ๐‘ก๐‘œ ๐‘›๐‘œ๐‘ก ๐‘—๐‘ข๐‘ ๐‘ก ๐‘๐‘Ÿ๐‘’๐‘Ž๐‘ก๐‘’ ๐‘๐‘ข๐‘ก ๐‘Ž๐‘‘๐‘ฃ๐‘Ž๐‘›๐‘๐‘’ ๐‘ก๐‘Ÿ๐‘Ž๐‘›๐‘ ๐‘“๐‘œ๐‘Ÿ๐‘š๐‘Ž๐‘ก๐‘–๐‘ฃ๐‘’ ๐‘‘๐‘Ÿ๐‘ข๐‘” ๐‘๐‘Ž๐‘›๐‘‘๐‘–๐‘‘๐‘Ž๐‘ก๐‘’๐‘  ๐‘“๐‘œ๐‘Ÿ ๐‘‘๐‘–๐‘Ž๐‘”๐‘›๐‘œ๐‘ ๐‘–๐‘  ๐‘Ž๐‘›๐‘‘ ๐‘กโ„Ž๐‘’๐‘Ÿ๐‘Ž๐‘๐‘ฆ ๐‘œ๐‘“ ๐‘๐‘Ž๐‘ก๐‘–๐‘’๐‘›๐‘ก๐‘  ๐‘ค๐‘–๐‘กโ„Ž ๐‘ ๐‘’๐‘Ÿ๐‘–๐‘œ๐‘ข๐‘  ๐‘‘๐‘–๐‘ ๐‘’๐‘Ž๐‘ ๐‘’๐‘  ๐‘Ž๐‘  ๐‘๐‘Ž๐‘›๐‘๐‘’๐‘Ÿ.โ€

๐ด๐‘›๐‘‘๐‘Ÿ๐‘’๐‘Ž๐‘  ๐น๐‘–๐‘›๐‘ก๐‘’๐‘™๐‘š๐‘Ž๐‘›๐‘›, ๐ถ๐ธ๐‘‚ ๐‘œ๐‘“ ๐‘ƒ๐ด๐ผ๐ท, ๐‘ โ„Ž๐‘Ž๐‘Ÿ๐‘’๐‘‘: "๐ด๐ผ ๐‘Ž๐‘›๐‘‘ ๐‘โ„Ž๐‘’๐‘š๐‘–๐‘ ๐‘ก๐‘Ÿ๐‘ฆ ๐‘Ž๐‘Ÿ๐‘’ ๐‘ก๐‘ค๐‘œ ๐‘๐‘œ๐‘ค๐‘’๐‘Ÿ๐‘“๐‘ข๐‘™ ๐‘ก๐‘œ๐‘œ๐‘™๐‘ , ๐‘๐‘ข๐‘ก ๐‘กโ„Ž๐‘’๐‘ฆ ๐‘ค๐‘œ๐‘Ÿ๐‘˜ ๐‘๐‘’๐‘ ๐‘ก ๐‘คโ„Ž๐‘’๐‘› ๐‘๐‘œ๐‘š๐‘๐‘–๐‘›๐‘’๐‘‘. ๐ต๐‘ฆ ๐‘ค๐‘œ๐‘Ÿ๐‘˜๐‘–๐‘›๐‘” ๐‘ค๐‘–๐‘กโ„Ž ๐ธ๐‘›๐‘Ž๐‘š๐‘–๐‘›๐‘’ ๐‘Ž๐‘›๐‘‘ ๐ถโ„Ž๐‘’๐‘š๐‘ ๐‘๐‘Ž๐‘๐‘’, ๐‘ค๐‘’โ€™๐‘Ÿ๐‘’ ๐‘’๐‘›โ„Ž๐‘Ž๐‘›๐‘๐‘–๐‘›๐‘” ๐‘œ๐‘ข๐‘Ÿ ๐‘Ž๐‘๐‘–๐‘™๐‘–๐‘ก๐‘ฆ ๐‘ก๐‘œ ๐‘–๐‘‘๐‘’๐‘›๐‘ก๐‘–๐‘“๐‘ฆ ๐‘๐‘Ÿ๐‘œ๐‘š๐‘–๐‘ ๐‘–๐‘›๐‘” ๐‘‘๐‘Ÿ๐‘ข๐‘” ๐‘๐‘Ž๐‘›๐‘‘๐‘–๐‘‘๐‘Ž๐‘ก๐‘’๐‘  ๐‘Ž๐‘›๐‘‘ ๐‘๐‘Ÿ๐‘–๐‘›๐‘” ๐‘กโ„Ž๐‘’๐‘š ๐‘ก๐‘œ ๐‘๐‘™๐‘–๐‘›๐‘–๐‘๐‘Ž๐‘™ ๐‘‘๐‘’๐‘ฃ๐‘’๐‘™๐‘œ๐‘๐‘š๐‘’๐‘›๐‘ก ๐‘š๐‘ข๐‘โ„Ž ๐‘“๐‘Ž๐‘ ๐‘ก๐‘’๐‘Ÿ." ๐ท๐‘Ÿ. ๐‘€๐‘Žโ„Ž๐‘š๐‘œ๐‘œ๐‘‘ ๐‘๐‘Ž๐‘ง๐‘Ž๐‘Ÿ๐‘–, ๐ถ๐‘‚๐‘‚ ๐‘œ๐‘“ ๐‘ƒ๐ด๐ผ๐ท, ๐‘Ž๐‘‘๐‘‘๐‘’๐‘‘: "๐‘‚๐‘›๐‘’ ๐‘œ๐‘“ ๐‘œ๐‘ข๐‘Ÿ ๐‘˜๐‘’๐‘ฆ ๐‘”๐‘œ๐‘Ž๐‘™๐‘  ๐‘–๐‘  ๐‘ก๐‘œ ๐‘“๐‘ข๐‘Ÿ๐‘กโ„Ž๐‘’๐‘Ÿ ๐‘–๐‘š๐‘๐‘Ÿ๐‘œ๐‘ฃ๐‘’ ๐‘œ๐‘ข๐‘Ÿ ๐ด๐ผ ๐‘๐‘Ÿ๐‘’๐‘‘๐‘–๐‘๐‘ก๐‘–๐‘œ๐‘›๐‘  ๐‘๐‘ฆ ๐‘–๐‘›๐‘ก๐‘’๐‘”๐‘Ÿ๐‘Ž๐‘ก๐‘–๐‘›๐‘” ๐‘š๐‘œ๐‘Ÿ๐‘’ ๐‘’๐‘ฅ๐‘๐‘’๐‘Ÿ๐‘–๐‘š๐‘’๐‘›๐‘ก๐‘Ž๐‘™ ๐‘ฃ๐‘Ž๐‘™๐‘–๐‘‘๐‘Ž๐‘ก๐‘–๐‘œ๐‘›. ๐‘‡โ„Ž๐‘–๐‘  ๐‘๐‘œ๐‘™๐‘™๐‘Ž๐‘๐‘œ๐‘Ÿ๐‘Ž๐‘ก๐‘–๐‘œ๐‘› ๐‘’๐‘›๐‘ ๐‘ข๐‘Ÿ๐‘’๐‘  ๐‘กโ„Ž๐‘Ž๐‘ก ๐‘’๐‘ฃ๐‘’๐‘Ÿ๐‘ฆ ๐‘ ๐‘ก๐‘’๐‘ โ€” ๐‘“๐‘Ÿ๐‘œ๐‘š ๐ด๐ผ-๐‘‘๐‘Ÿ๐‘–๐‘ฃ๐‘’๐‘› ๐‘ ๐‘๐‘Ÿ๐‘’๐‘’๐‘›๐‘–๐‘›๐‘” ๐‘ก๐‘œ ๐‘Ÿ๐‘’๐‘Ž๐‘™-๐‘ค๐‘œ๐‘Ÿ๐‘™๐‘‘ ๐‘ก๐‘’๐‘ ๐‘ก๐‘–๐‘›๐‘” โ€” ๐‘ ๐‘ก๐‘Ÿ๐‘’๐‘›๐‘”๐‘กโ„Ž๐‘’๐‘›๐‘  ๐‘กโ„Ž๐‘’ ๐‘Ÿ๐‘’๐‘™๐‘–๐‘Ž๐‘๐‘–๐‘™๐‘–๐‘ก๐‘ฆ ๐‘Ž๐‘›๐‘‘ ๐‘ ๐‘ข๐‘๐‘๐‘’๐‘ ๐‘  ๐‘œ๐‘“ ๐‘œ๐‘ข๐‘Ÿ ๐‘‘๐‘–๐‘ ๐‘๐‘œ๐‘ฃ๐‘’๐‘Ÿ๐‘–๐‘’๐‘ ."

๐€๐›๐จ๐ฎ๐ญ ๐‚๐ก๐ž๐ฆ๐ฌ๐ฉ๐š๐œ๐ž
Chemspace is a global provider of drug discovery services. We can streamline hit finding by integrating our Computational Chemistry tools, Bioinformatics, and Machine Learning-based services for smarter drug discovery. By exploring ultra-large chemical spaces, we deliver high-quality hit molecules for discovery projects. Our integrated projects combine hit identification services with biological validation, providing a seamless path from hit identification to pre-clinical studies.
For more information, visit https://chem-space.com

๐€๐›๐จ๐ฎ๐ญ ๐„๐ง๐š๐ฆ๐ข๐ง๐ž
Enamine is a scientifically driven integrated discovery Contract Research Organization with unique partnering opportunities in exploring chemical space. The company combines access to the in-house produced screening compounds (4.4M in stock) and building blocks (300K in stock) with a comprehensive platform of integrated discovery services, including discovery biology, to advance and accelerate the efforts in drug discovery.
For more information, visit https://enamine.net

๐€๐›๐จ๐ฎ๐ญ ๐๐ก๐š๐ซ๐ฆ๐€๐ˆ ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐†๐ฆ๐›๐‡
PharmAI Discovery GmbH, based in Dresden, Germany, is an innovative biotechnology company specializing in both AI-driven drug discovery and drug development. PharmAI Discovery accelerates the identification, optimization, and clinical translation of novel therapeutics by combining cutting-edge artificial intelligence with experimental validation.
For more information, visit https://pharmai-discovery.com

๐…๐จ๐ซ ๐ฆ๐ž๐๐ข๐š ๐ข๐ง๐ช๐ฎ๐ข๐ซ๐ข๐ž๐ฌ, ๐ฉ๐ฅ๐ž๐š๐ฌ๐ž ๐œ๐จ๐ง๐ญ๐š๐œ๐ญ:

๐…๐จ๐ซ ๐‚๐ก๐ž๐ฆ๐ฌ๐ฉ๐š๐œ๐ž

Olga Tarkhanova, Ph.D.
Email: o.tarkhanova@chem-space.com
https://chem-space.com

๐…๐จ๐ซ ๐„๐ง๐š๐ฆ๐ข๐ง๐ž

Yurii Moroz, Ph.D.
Email: yurii.moroz@enamine.net
https://enamine.net

๐…๐จ๐ซ ๐๐ก๐š๐ซ๐ฆ๐€๐ˆ ๐ƒ๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ ๐†๐ฆ๐›๐‡

Mahmood Nazari. Ph.D.
Email: info@pharmai-discovery.com
https://pharmai-discovery.com

Yurii Moroz, Ph.D.
Enamine Ltd.
email us here

Powered by EIN Presswire

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry, Science

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release

Lung Cancer News Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow us on Facebook and connect with us on LinkedIn

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement